Camphor toxicity: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "==Treatment==" to "==Management==") |
|||
| Line 3: | Line 3: | ||
*FDA limits over the counter preparations to 11%<ref>United States Food and Drug Administration. Proposed rules: external analgesic drug products for over-the-counter human use; tentative final monograph. Fed Reg 1983</ref> | *FDA limits over the counter preparations to 11%<ref>United States Food and Drug Administration. Proposed rules: external analgesic drug products for over-the-counter human use; tentative final monograph. Fed Reg 1983</ref> | ||
*Highly lipophilic, widely and rapidly distributed, symptom onset 5-15 minutes | *Highly lipophilic, widely and rapidly distributed, symptom onset 5-15 minutes | ||
*CNS | *CNS stimulant when ingested | ||
==Clinical Features== | ==Clinical Features== | ||
Revision as of 19:23, 6 September 2017
Background
- Common topical agent for pain relief, wart removal, osteoarthritis, cold sores
- FDA limits over the counter preparations to 11%[1]
- Highly lipophilic, widely and rapidly distributed, symptom onset 5-15 minutes
- CNS stimulant when ingested
Clinical Features
- Nausea, vomiting, abdominal pain
- Oral burning, headache
- Vertigo, confusion, agitation
- Seizure, respiratory depression, coma
- Hepatitis and liver failure
Management
- Aggressive supportive care[2]
- Benzodiazepines for seizure
- Intubation and mechanical ventilation as needed
- Charcoal not likely effective